

Human PIGF Alexa Fluor® 647-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 1038864

Catalog Number: FAB2643R

100 µg

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human PIGF in direct ELISAs.
Source	Monoclonal Mouse IgG _{2B} Clone # 1038864
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	E. coli-derived human PIGF Ala21-Arg149 Accession # P49763-2
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

Immunocytochemistry Optimal dilution of this antibody should be experimentally determined

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

BACKGROUND

Stability & Storage

Placenta Growth Factor (PIGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1, 2). Alternative splicing results in at least three human mature PIGF forms containing 131 (PIGF-1), 152 (PIGF-2), and 203 (PIGF-3) amino acids (aa) respectively (1, 2). Only PIGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus (1). Human PIGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PIGF, respectively. PIGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers (3). Mammalian cells expressing PIGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells (1, 4-6). Circulating PIGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia (7). However, deletion of PIGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PIGF show impaired angiogenesis in response to ischemia (8). PIGF binds and signals through VEGF R1/FIt-1 but not VEGF R2/FIk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PIGF and VEGF therefore compete for binding to VEGF R1, allowing high PIGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis (1, 4, 8, 9). However, PIGF (especially PIGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 (3, 4). PIGF-2, but not PLGF-1, shows heparin-dependent binding of Neuropilin (Npn)-1 and Npn-2 (10, 11). PIGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis (5, 6, 8, 12-15). PIGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension (16).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/20/2025 Page 1 of 1

Global | bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL: 1.612.379.2956

Bio-Techne®

USA | TEL: 800.343.7475 Canada | TEL: 855.668.8722 Europe | Middle East | Africa TEL: +44.0.1235.529449 China | info.cn@bio-techne.com TEL: 400.821.3475